|
|
   Upadacitinib
|
|
|
| appearance as argument number 1 |
|
|
| (diseaseMedicine Upadacitinib RheumatoidArthritis Ingesting) | Medicine.kif 5547-5547 | Upadacitinib is disease treatment rheumatoid arthritis for ingesting |
| (documentation Upadacitinib EnglishLanguage "Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active RheumatoidArthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated. It was developed by the biotech company AbbVie. Common side effects include upper respiratory tract infections (common cold, sinus infections), Nausea, Cough, and Fever.[from Wikipedia]") | Medicine.kif 5539-5546 | |
| (sideEffect Upadacitinib Fever) | Medicine.kif 5549-5549 | Fever is a side effect of taking upadacitinib |
| (sideEffect Upadacitinib Nausea) | Medicine.kif 5548-5548 | Nausea is a side effect of taking upadacitinib |
| (subclass Upadacitinib Medicine) | Medicine.kif 5537-5537 | Upadacitinib is a subclass of medicine |
| appearance as argument number 2 |
|
|
| (subclass Rinvoq Upadacitinib) | Medicine.kif 5552-5552 | Rinvoq is a subclass of upadacitinib |
| (termFormat EnglishLanguage Upadacitinib "upadacitinib") | Medicine.kif 5550-5550 |
|
|
|